碳离子点扫描强子弧放射治疗的首次剂量测定和生物学验证

IF 2.2 Q3 ONCOLOGY

Advances in Radiation Oncology Pub Date : 2024-09-11 DOI:10.1016/j.adro.2024.101611

Thomas Tessonnier PhD , Domenico Ivan Filosa MS , Celine Karle MS , Filipa Baltazar MS , Lorenzo Manti PhD , Lars Glimelius MS , Thomas Haberer PhD , Amir Abdollahi PhD, MD , Juergen Debus PhD, MD , Stewart Mein PhD , Ivana Dokic PhD , Andrea Mairani PhD

{"title":"碳离子点扫描强子弧放射治疗的首次剂量测定和生物学验证","authors":"Thomas Tessonnier PhD , Domenico Ivan Filosa MS , Celine Karle MS , Filipa Baltazar MS , Lorenzo Manti PhD , Lars Glimelius MS , Thomas Haberer PhD , Amir Abdollahi PhD, MD , Juergen Debus PhD, MD , Stewart Mein PhD , Ivana Dokic PhD , Andrea Mairani PhD","doi":"10.1016/j.adro.2024.101611","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Spot-scanning hadron arc radiation therapy (SHArc) is a novel delivery technique for ion beams with potentially improved dose conformity and dose-averaged linear energy transfer (LET<sub>d</sub>) redistribution. The first dosimetric validation and in vitro verification of carbon ion arc delivery is presented.</div></div><div><h3>Methods and Materials</h3><div>Intensity-modulated particle therapy (IMPT) and SHArc plans were designed to deliver homogeneous physical dose or biological dose in a cylindrical polymethyl methacrylate (PMMA) phantom. Additional IMPT carbon plans were optimized for testing different LET<sub>d</sub>-boosting strategies. Verifications of planned doses were performed with an ionization chamber, and a clonogenic survival assay was conducted using A549 cancer lung cell line. Radiation-induced nuclear 53BP1 foci were assessed to evaluate the cellular response in both normoxic and hypoxic conditions.</div></div><div><h3>Results</h3><div>Dosimetric measurements and clonogenic assay results showed a good agreement with planned dose and survival distributions. Measured survival fractions and foci confirmed carbon ions SHArc as a potential modality to overcome hypoxia-induced radioresistance. LET<sub>d</sub>-boosted IMPT plans reached similar LET<sub>d</sub> in the target as in SHArc plans, promising similar features against hypoxia but at the cost of an increased entrance dose. SHArc resulted, however, in a lower dose bath but in a larger volume around the target.</div></div><div><h3>Conclusions</h3><div>The first proof-of-principle of carbon ions SHArc delivery was performed, and experimental evidence suggests this novel modality as an attractive approach for treating hypoxic tumors.</div></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 12","pages":"Article 101611"},"PeriodicalIF":2.2000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"First Dosimetric and Biological Verification for Spot-Scanning Hadron Arc Radiation Therapy With Carbon Ions\",\"authors\":\"Thomas Tessonnier PhD , Domenico Ivan Filosa MS , Celine Karle MS , Filipa Baltazar MS , Lorenzo Manti PhD , Lars Glimelius MS , Thomas Haberer PhD , Amir Abdollahi PhD, MD , Juergen Debus PhD, MD , Stewart Mein PhD , Ivana Dokic PhD , Andrea Mairani PhD\",\"doi\":\"10.1016/j.adro.2024.101611\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Spot-scanning hadron arc radiation therapy (SHArc) is a novel delivery technique for ion beams with potentially improved dose conformity and dose-averaged linear energy transfer (LET<sub>d</sub>) redistribution. The first dosimetric validation and in vitro verification of carbon ion arc delivery is presented.</div></div><div><h3>Methods and Materials</h3><div>Intensity-modulated particle therapy (IMPT) and SHArc plans were designed to deliver homogeneous physical dose or biological dose in a cylindrical polymethyl methacrylate (PMMA) phantom. Additional IMPT carbon plans were optimized for testing different LET<sub>d</sub>-boosting strategies. Verifications of planned doses were performed with an ionization chamber, and a clonogenic survival assay was conducted using A549 cancer lung cell line. Radiation-induced nuclear 53BP1 foci were assessed to evaluate the cellular response in both normoxic and hypoxic conditions.</div></div><div><h3>Results</h3><div>Dosimetric measurements and clonogenic assay results showed a good agreement with planned dose and survival distributions. Measured survival fractions and foci confirmed carbon ions SHArc as a potential modality to overcome hypoxia-induced radioresistance. LET<sub>d</sub>-boosted IMPT plans reached similar LET<sub>d</sub> in the target as in SHArc plans, promising similar features against hypoxia but at the cost of an increased entrance dose. SHArc resulted, however, in a lower dose bath but in a larger volume around the target.</div></div><div><h3>Conclusions</h3><div>The first proof-of-principle of carbon ions SHArc delivery was performed, and experimental evidence suggests this novel modality as an attractive approach for treating hypoxic tumors.</div></div>\",\"PeriodicalId\":7390,\"journal\":{\"name\":\"Advances in Radiation Oncology\",\"volume\":\"9 12\",\"pages\":\"Article 101611\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Radiation Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S245210942400174X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245210942400174X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的点扫描强子弧放射治疗（SHArc）是一种新型离子束输送技术，具有潜在的改进剂量一致性和剂量平均线性能量转移（LETd）再分布的能力。方法与材料设计了强度调制粒子疗法（IMPT）和 SHArc 计划，以在圆柱形聚甲基丙烯酸甲酯（PMMA）模型中提供均匀的物理剂量或生物剂量。还优化了其他 IMPT 碳计划，以测试不同的 LETd 增强策略。利用电离室对计划剂量进行了验证，并使用 A549 癌症肺细胞系进行了克隆存活试验。对辐射诱导的核 53BP1 病灶进行了评估，以评价细胞在常氧和缺氧条件下的反应。测量的存活率和病灶证实，碳离子 SHArc 是克服缺氧引起的放射抗性的一种潜在方式。LETd增强型IMPT计划在靶区达到的LETd与SHArc计划相似，具有类似的抗缺氧功能，但代价是入口剂量增加。结论首次进行了碳离子 SHArc 输送的原理验证，实验证据表明这种新型模式是治疗缺氧性肿瘤的一种有吸引力的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

First Dosimetric and Biological Verification for Spot-Scanning Hadron Arc Radiation Therapy With Carbon Ions

Purpose

Spot-scanning hadron arc radiation therapy (SHArc) is a novel delivery technique for ion beams with potentially improved dose conformity and dose-averaged linear energy transfer (LET_d) redistribution. The first dosimetric validation and in vitro verification of carbon ion arc delivery is presented.

Methods and Materials

Intensity-modulated particle therapy (IMPT) and SHArc plans were designed to deliver homogeneous physical dose or biological dose in a cylindrical polymethyl methacrylate (PMMA) phantom. Additional IMPT carbon plans were optimized for testing different LET_d-boosting strategies. Verifications of planned doses were performed with an ionization chamber, and a clonogenic survival assay was conducted using A549 cancer lung cell line. Radiation-induced nuclear 53BP1 foci were assessed to evaluate the cellular response in both normoxic and hypoxic conditions.

Results

Dosimetric measurements and clonogenic assay results showed a good agreement with planned dose and survival distributions. Measured survival fractions and foci confirmed carbon ions SHArc as a potential modality to overcome hypoxia-induced radioresistance. LET_d-boosted IMPT plans reached similar LET_d in the target as in SHArc plans, promising similar features against hypoxia but at the cost of an increased entrance dose. SHArc resulted, however, in a lower dose bath but in a larger volume around the target.

Conclusions

The first proof-of-principle of carbon ions SHArc delivery was performed, and experimental evidence suggests this novel modality as an attractive approach for treating hypoxic tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

4.60

自引率

4.30%

发文量

208

审稿时长

98 days

期刊介绍： The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing: Clinical trial reports and reanalyses. Basic science original reports. Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews. Case reports documenting unusual problems and solutions. High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series. Timely critical reviews on important topics in radiation oncology, such as side effects. Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation. Articles on safety and quality in radiation therapy. Essays on clinical experience. Articles on practice transformation in radiation oncology, in particular: Aspects of health policy that may impact the future practice of radiation oncology. How information technology, such as data analytics and systems innovations, will change radiation oncology practice. Articles on imaging as they relate to radiation therapy treatment.